Antiviral activity of NMSO3 against adenovirus in vitro

Antiviral Research

Volumn 52, Issue 3, 2001, Pages 281-288

  Kaneko, Hisatoshi ^a   Kato, Keiichiro ^a   Mori, Shuichi ^a   Shigeta, Shiro ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus; Adsorption inhibitor; Anti adenovirus; MTT method; NMSO3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIVIRUS AGENT; CIDOFOVIR; NMSO 3; SIALIC ACID DERIVATIVE; SODIUM[2,2 BIS(DOCOSYLOXYMETHYL)PROPYL 5 ACETOAMIDO 3,5 DIDEOXYL 4,7,8,9 TETRA O (SODIUMOXYSULFONYL) DEXTRO GLYCERO A DEXTRO GALACTO 2 NONULOPYRANOSID]ONATE; UNCLASSIFIED DRUG; ZALCITABINE;

ADENOVIRUS 2; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; PRIORITY JOURNAL; VIRUS ADSORPTION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; ADSORPTION; ANTIVIRAL AGENTS; EVALUATION STUDIES; HUMANS; LIPIDS; N-ACETYLNEURAMINIC ACID; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0034784031     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00167-X     Document Type: Article

References (30)

1. Adenovirus type 37 uses sialic acid as a cellular receptor
2. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: Sialic acid versus alpha(v) integrins
3. Isolation of common receptor for Coxsackie B viruses and adenoviruses 2 and 5
4. Therapeutic potential of HPMPC as an antiviral drug
5. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively
6. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model
7. Human adenovirus-host cell interactions: Comparative study with members of subgroups B and C
8. Epidemiology of epidemic keratoconjunctivitis
9. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic-GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro
10. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model
11. Adenovirus keratoconjunctivitis
12. Treatment of adenoviral conjunctivitis with topical cidofovir
13. Stepwise dismantling of adenovirus 2 during into cells
14. The role of the nuclear pore complex in adenovirus DNA entry
15. Biochemical studies an adenovirus multiplication, VI. Properties of highly purified tumorigenic human adenoviruses and their DNA's
16. Adenovirus in the immunocompromised host
17. Cidofovir 0.2% with and without cyclosporin A 1% as a topical treatment of adenoviral keratoconjunctivitis. A controlled clinical pilot trial
18. Adenovirus type 5 fiber knob binds to MHC alpha2 domain at the surface of human epithelial and B lymphoblastoid cells
19. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequence of the viral envelope glycoproteins
20. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo
21. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method
22. Evaluation of the efficacy of 2′,3′-dideoxycydine against adenovirus infection in a mouse pneumonia model
23. Inhibitory activity of 3′-fluoro-2′-deoxythymidine and related nucleoside analoges against adenovirus in vitro
24. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynuculoosides in vitro
25. Selective inhibition of human cytomegalovirus DNA synthesis by HPMPC
26. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model
27. Recent progress in antiviral chemotherapy for respiratory syncytial virus infections
28. Molecular composition of the adenovirus type 2 virion
29. Genetic variability of adenoviruses
30. Adenovirus pneumonia with severe sequelae in an immunocompetent adult